Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2348)	4/23/2010 11:10:33 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ONXX opened with an UG and is trading again above the $30 level.<g> The stock traded as high as $31.10 but that was below the resistance from the Apr19H of $31.22 and the March 16 H of $33.48 <g> bigcharts.marketwatch.com This week PFE said that patients who were treated with Sutent were not surviving as long as patients who were treated with Nexavar, and PFE decided to give up on Sutent as the drug was also showing more side effects.>g> Nexavar has been approved for the treatment of liver Ca and advanced kidney Ca.It is also under trials in a variety of other neoplasms. Besides Nevaxar, ONXX has other drug candidates in its pipeline at various stages of clinical testing, including carfilzomib, a proteasome inhibitor, that is been tested for treatment of MM and some solid tumors, and ONX 0801, an alpha-folate inhibitor that in a PI. But in spite of better revenues for 4 consecutive Qs, earnings last Yr. were lower than in 2008 and the EE for 2010 are significantly lower $0.15 vs. $0.84 in 2009 <g> The stock is not yet off from the DT coming from its 2007 H at $61.18 bigcharts.marketwatch.com Bernard